Designing viral vector clearance studies for CGT products according to ICH Q5A (R2): part 1

Cell and Gene Therapy Insights 2023; 9(4), 2001

DOI: 10.18609/cgti.2023.067

Published: 19 May 2023
Tareq Jaber

Watch the video or view the poster to learn more about:

  • Starting material considerations for gene therapy products
  • Limitations of traditional viral clearance processes 
  • How to determine the appropriate log reduction factor for your product
  • Case studies provided in ICH Q5A (R2)